Clinical Trial Update: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease [Phase 2, Phase 3]

View source ↗

Summary

A Regeneron trial evaluated high-dose aflibercept for diabetic macular edema in diabetic eye disease. The Phase 2/3 study has completed, and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Diabetic Macular Edema, Type 1 Diabetes Mellitus | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-11-21